Hydrochlorothiazide/Metoprolol Succinate

琥珀酸美托洛尔/氢氯噻嗪

Report date: 2022/04/07 09:13:28

Base Information

Drug NameHydrochlorothiazide/Metoprolol Succinate
Drug Alias Name氢氯噻嗪/琥珀酸美托洛尔Metoprolol Succinate/Hydrochlorothiazide琥珀酸美托洛尔+氢氯噻嗪Metoprolol extended release+Hydrochlorothiazide tablet氢氯噻嗪+琥珀酸美托洛尔 +[9
ClassificationSmall molecules
Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsBeta-1 adrenergic receptor antagonists
TargetsThiazide-sensitive sodium-chloride cotransporterBeta-1 adrenergic receptor
Therapy Area/IndicationsHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2006/08/28
Country/TerritoryUnited States
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcConcordia
Active IndicationsN/A
Inactive IndicationsHypertension

Other Information

ATC CodeC03AX01C07BB52
Related LinksN/A